Skip to Main Content
Contribute Try STAT+ Today

When Bluebird Bio secured European approval for its gene therapy to treat beta thalassemia in 2019, the biotech entered pricing negotiations confident that a “shared risk” plan could convince governments to pay $1.8 million per patient for the one-time, potentially curative treatment.

But two years later, Bluebird is pulling its gene therapy, called Zynteglo, from Germany after government officials would not budge from an offer to pay less than half of the company’s list price. The stalemate is a significant setback for Bluebird’s business ambitions in Europe, but it also raises broader questions about whether Europe can ever become a viable commercial market for other expensive gene therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.